Loading
A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors. ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 255 participants. Primary completion is estimated at 2027-12-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: VBC103. Registered primary measures: Incidence of dose-limiting toxicities (DLT) as defined in the protocol; Incidence of Serious Adverse Events.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares VelaVigo, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares VelaVigo, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/